Article

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer

2025-02-08

Abstract excerpt

Prostate cancer (PCa) is the second most lethal cancer in men in the United States. African American (AA) men have twice the incidence and death rate from the disease than European American (EA) men. Early-stage PCa is treated with hormone deprivation therapy, although patients frequently experience relapse. Advanced stage PCa is associated with increased expression and activity of the DNA damage/repair pathway en...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8e91a834-3ea7-501d-b539-f8051a89cb60
DOI: 10.1101/2025.02.05.636297

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancerDOI 10.1101/2025.02.05.636297Read

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read

Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?Semantic proximity Read

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.Semantic proximity Read

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read

Dual Roles of PARP-1 Promote Cancer Growth and ProgressionSemantic proximity Read

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read

Development of PARP inhibitors in advanced prostate cancerSemantic proximity Read

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read